- Home
- WST vs LII Comparison
WST vs LII Comparison
Compare WST & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- LII
- Stock Information
- Founded
- WST 1923
- LII 1895
- Country
- WST United States
- LII United States
- Employees
- WST N/A
- LII N/A
- Industry
- WST Medical/Dental Instruments
- LII Industrial Machinery/Components
- Sector
- WST Health Care
- LII Industrials
- Exchange
- WST Nasdaq
- LII Nasdaq
- Market Cap
- WST 15.6B
- LII 20.6B
- IPO Year
- WST N/A
- LII 1999
- Fundamental
- Price
- WST $221.97
- LII $600.51
- Analyst Decision
- WST Buy
- LII Hold
- Analyst Count
- WST 7
- LII 11
- Target Price
- WST $331.67
- LII $606.30
- AVG Volume (30 Days)
- WST 645.3K
- LII 353.1K
- Earning Date
- WST 07-24-2025
- LII 07-23-2025
- Dividend Yield
- WST 0.38%
- LII 0.87%
- EPS Growth
- WST N/A
- LII 30.10
- EPS
- WST 6.37
- LII 22.45
- Revenue
- WST $2,895,800,000.00
- LII $5,366,800,000.00
- Revenue This Year
- WST $3.38
- LII $3.33
- Revenue Next Year
- WST $5.85
- LII $5.56
- P/E Ratio
- WST $34.63
- LII $26.49
- Revenue Growth
- WST N/A
- LII 7.78
- 52 Week Low
- WST $187.43
- LII $500.10
- 52 Week High
- WST $352.33
- LII $682.50
- Technical
- Relative Strength Index (RSI)
- WST 54.71
- LII 64.48
- Support Level
- WST $219.60
- LII $588.69
- Resistance Level
- WST $225.46
- LII $606.45
- Average True Range (ATR)
- WST 4.88
- LII 12.31
- MACD
- WST -0.09
- LII 4.51
- Stochastic Oscillator
- WST 63.62
- LII 91.31
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.